NeoGenomics expects FY23 Adjusted EBITDA loss of $(27)M-$(22)M.
NeoGenomics Forecasts FY23 Revenues Of $545M-$555M Vs. $535.08M Estimate
NeoGenomics expects FY23 Adjusted EBITDA loss of $(27)M-$(22)M.
Related Posts
Morgan Stanley Maintains Overweight on Hippo Holdings, Adjusts PT To $51.5 (1-for-25 reverse stock split)
Morgan Stanley analyst Michael Phillips maintains Hippo Holdings (NYSE:HIPO) with a Overweight, adjusts PT to $51.5 (1-for-25 reverse stock split).
Mullen Streamlines Business Operations To Focus On Near Term Commercial Opportunities, Actions Are Expected To Drive An Estimated $170M Reduction In The Co’s Operating And Investing Cash Flow Expenses Over The Next 12 Months When Compared YoY
Cost saving initiatives aimed at reducing operating and investing cash flows by approximately $170 million over the next 12 months when compared to operating and investing cash flows reported for the 12 months ended